Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp demonstrates a strong potential for continued growth, supported by vaccine response rates for its 100ug candidate that are comparable to those of Shingrix, while also exhibiting significantly better tolerability. The company’s shingles vaccine candidate has achieved results that align well with management's immunogenicity and tolerability goals, reinforcing the efficacy of its innovative platform. Furthermore, positive results related to CD4+ T-cell responses for its Z-1018 candidate further bolster Dynavax's outlook, making it a compelling player in the biopharmaceutical landscape.

Bears say

Dynavax Technologies Corp faces significant risks in developing its product candidates, as any future candidates may fail to meet efficacy endpoints or exhibit safety issues that could impede their approval and commercialization. The company also faces challenges related to market conditions and competition that could hinder the effective commercialization of its proprietary candidates, further compromising its revenue potential. Additionally, there is a risk associated with the ability to secure acceptable partnership terms for its candidates, which could jeopardize successful market launches and adversely impact the company's financial outlook.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.